title: Effects of EPC capture stent and CD34+ mobilization in acute myocardial infarction.
abstract: OBJECTIVE
  Percutaneous coronary intervention (PCI) is the gold standard for the treatment of acute myocardial infarction (AMI), with the main limitation of in-stent restenosis for BMS and late stent thrombosis (ST) for both BMS and DES. Endothelial progenitor cells (EPC) CD34+ capture stents, promoting vascular healing, may be advantageous in preventing ST. Aim of the study is to evaluate the outcomes of AMI patients treated with EPC CD34+ capture stent and describe the mobilization kinetics of CD34+ and their clinical correlation.
  
  
  METHODS
  Fifty AMI patients underwent primary PCI with EPC CD34+ capture stent. Serial assays of CD34+ were performed by flow-cytometric analysis.
  
  
  RESULTS
  Procedural success rate was 100%. At six-months follow-up cardiac death, myocardial infarction, target lesion revascularization (TLR) and target vessel revascularization (TVR) occurred respectively in 2%, 4%, 10% and 12% of patients. No case of ST was observed. The MACE-free survival was 81,2%. The mean peak value of plasmatic CD34+ was 4.69±3.76 cells/μL. A positive correlation was found between CD34+ concentration, age and infarct area. No correlation was detected between CD34+ concentration and occurrence of TVR, TLR and MACE.
  
  
  CONCLUSIONS
  EPC capture stent implantation seems to be safe and effective in the clinical setting of AMI, representing a possible alternative to BMS and DES. CD34+ cells plasmatic concentration seems not to correlate to coronary restenosis and atheromasic disease progression.
authors.affiliation: Department of Cardiovascular and Thoracic Diseases, San Giovanni Battista University HospitalTurin, Italy. paolo.scacciatella@tin.it
authors.forename: P
authors.initials: P
authors.lastname: Scacciatella
authors.forename: M
authors.initials: M
authors.lastname: D'Amico
authors.forename: M
authors.initials: M
authors.lastname: Pennone
authors.forename: F
authors.initials: F
authors.lastname: Conrotto
authors.forename: E
authors.initials: E
authors.lastname: Meliga
authors.forename: T
authors.initials: T
authors.lastname: Usmiani
authors.forename: I
authors.initials: I
authors.lastname: Meynet
authors.forename: M
authors.initials: M
authors.lastname: Gunetti
authors.forename: I
authors.initials: I
authors.lastname: Ferrero
authors.forename: D
authors.initials: D
authors.lastname: Rustichelli
authors.forename: F
authors.initials: F
authors.lastname: Fagioli
authors.forename: S
authors.initials: S
authors.lastname: Marra
mesh_terms: D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D001772:Blood Cell Count; D015897:Comorbidity; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control / Q000601:surgery; D003328:Coronary Thrombosis / Q000453:epidemiology / Q000517:prevention & control; D018572:Disease-Free Survival; D004730:Endothelium, Vascular / Q000502:physiology; D005260:Female; D005500:Follow-Up Studies; D019650:Hematopoietic Stem Cell Mobilization; D006801:Humans; D007902:Length of Stay / Q000706:statistics & numerical data; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation* / Q000379:methods; D011183:Postoperative Complications / Q000453:epidemiology / Q000517:prevention & control; D011446:Prospective Studies; D012038:Regeneration; D012042:Registries; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D018952:Antigens, CD34